During Friday’s Morning trade, Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS), lost -3.01% to $0.28.
Aeterna Zentaris, declared that it has executed a definitive agreement with Ergomed PLC, following which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency.
David A. Dodd, Chairman, President and Chief Executive Officer of the Company remarked regarding the selection of Ergomed, “We have great confidence in Ergomed’s ability to conduct our confirmatory clinical study of Macrilen™ on plan and within budget. Ergomed’s performance as our clinical research organization supporting our pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer has been excellent. We are committed to Macrilen™ because of our confidence in its efficacy and safety and the medical need for such a convenient test in the absence of an FDA-approved diagnostic test for AGHD.”
Miroslav Reljanovic, M.D., CEO of Ergomed said, “We are delighted that Aeterna Zentaris has selected us to manage their confirmatory study of Macrilen™. We have a strong and deep working relationship with the Company’s scientific staff and hold them in the highest regard.”
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health.
Shares of Medtronic plc (NYSE:MDT), inclined 0.16% to $75.60, during its current trading session.
Medtronic plc, declared the U.S. Food and Drug Administration (FDA) approval and commercial launch of the Advisa SR MRI(TM) SureScan® single-chamber pacemaker with the 5076 MRI lead, which allows for magnetic resonance imaging (MRI) scans positioned on any region of the body without restrictions. The new system comprises the Advisa SR MRI pacemaker and a SureScan lead, which must be used together to be considered MR-conditional.
MRI is the standard of care in soft tissue imaging, providing information not seen with X-ray, ultrasound, or CT scan, and without exposing patients to ionizing radiation. MRI is critical for the early detection, diagnosis and treatment of many diseases, counting strokes, cancer, Alzheimer`s disease, and muscle, bone and back pain - all of which are prevalent among older adults.
It is estimated that 50-75 percent of patients with implantable cardiac devices will need an MRI scan over the lifetime of their device.1 Until the approval of MR-conditional pacemakers, patients with implanted devices were typically denied access to MRI procedures because of the potential for harmful interaction between the device and the MRI scanner.
Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group.
Finally, AFLAC Inc. (NYSE:AFL), gained 0.05%, and is now trading at $63.37.
Aflac Incorporated, declared that it has hired Frederick J. Crawford as executive vice president and chief financial officer, reporting to Aflac Chairman and Chief Executive Officer Daniel P. Amos. In his new role, which will be effective June 30, 2015, Crawford will be responsible for overseeing the financial administration of company operations.
As formerly declared, Kriss Cloninger III will remain as president of Aflac Incorporated, with a particular emphasis on capital and planned planning, in addition to assisting the company grow the business while ensuring solid profitability. Cloninger will also be working closely with Crawford as he assumes the chief financial officer role.
Aflac Incorporated, through its partner, American Family Life Assurance Company of Columbus, provides supplemental health and life insurance products. It operates through two segments, Aflac Japan and Aflac U.S.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
